Danbiosyst UK Limited
17Patents
0Active
17Granted
36Portfolio score
Filing activity: Jan 15, 1987 → Jun 15, 1998
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4904479A | Drug delivery system | Human Necessities | 252 | Expired |
| US5204108A | Transmucosal formulations of low molecular weight peptide drugs | Human Necessities | 204 | Expired |
| US5804212A | Small particle compositions for intranasal drug delivery | Human Necessities | 180 | Expired |
| US5707644A | Small particle compositions for intranasal drug delivery | Human Necessities | 145 | Expired |
| US5648095A | Preparation of microparticles | Performing Operations; Transporting | 137 | Expired |
| US5744166A | Drug delivery compositions | Human Necessities | 134 | Expired |
| US5690954A | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material | Human Necessities | 119 | Expired |
| US5629011A | Composition for nasal administration | Human Necessities | 116 | Expired |
| US5725871A | Drug delivery compositions comprising lysophosphoglycerolipid | Human Necessities | 108 | Expired |
| US5869103A | Polymer microparticles for drug delivery | Human Necessities | 107 | Expired |
| US5935604A | Nasal drug delivery composition containing nicotine | Human Necessities | 79 | Expired |
| US5863554A | Enhanced uptake drug delivery system | Human Necessities | 77 | Expired |
| US5840341A | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential | Emerging Cross-Sectional Technologies | 43 | Expired |
| US5554388A | Systemic drug delivery compositions comprising a polycationi substance | Human Necessities | 38 | Expired |
| US6001395A | Polymeric lamellar substrate particles for drug delivery | Emerging Cross-Sectional Technologies | 32 | Expired |
| US5792475A | Lymphatic delivery composition | Human Necessities | 22 | Expired |
| US5928669A | Lymphatic delivery methods | Human Necessities | 9 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.